Indication and Important Safety Information

Important Safety Information

Contraindications: MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, products of porcine or bovine origin; in patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders; in patients who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant; or in patients unable to cooperate with a physician-prescribed post-surgical rehabilitation program.

Warnings and Precautions:

Malignancy: The risk of MACI in patients with malignancy in the area of cartilage biopsy or implant is unknown. Expansion of malignant or dysplastic cells present in biopsy tissue during manufacture and subsequent implantation may be possible.
Transmissible infectious diseases: Because patients undergoing procedures associated with MACI are not routinely tested for transmissible infectious diseases, cartilage biopsy and MACI implant may carry risk of transmitting infectious diseases.
Presurgical Comorbidities: Local inflammation or active infection in the bone, joint, and surrounding soft tissue, meniscal pathology, cruciate ligament instability, and misalignment should be assessed and treated prior to or concurrent with MACI implantation.
Product Sterility: Final sterility test results are not available at the time of shipping.

Adverse Reactions: The most frequently occurring adverse reactions reported for MACI (≥5%) were arthralgia, tendonitis, back pain, joint swelling, and joint effusion. Serious adverse reactions reported for MACI were arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.

Specific Populations:

Use of MACI in pediatric patients (younger than 18 years of age) or in patients over 65 years of age has not been established.
The MACI implant is not recommended during pregnancy. For implantations post-pregnancy, the safety of breastfeeding to an infant has not been determined.

To report negative side effects, contact Vericel Corporation at 1-800-453-6948 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Indication

MACI^® is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

Limitations of Use

Effectiveness of MACI in joints other than the knee has not been established.

Safety and effectiveness of MACI in patients over the age of 55 years have not been established.

Summit Header

The Science of MACI. The Choice of Delivery.

July 11, 2025 05:00 PM CDT

Nashville, TN

Register Now

About the Program

Register today to attend the MACI Arthro Dinner Event during AOSSM:

The Science of MACI. The Choice of Delivery.

Featured topics will include:

MACI Introduction
MACI Arthro Overview
Case Presentation Panel

Arthroscopic delivery of MACI is for lesions ≤4 cm² accessible using an arthroscopic approach.

This program is sponsored by Vericel Corporation and is not eligible for CME credits.

Featured Presenters

Robert L. Parisien, MD

Robert L. Parisien, MD

Mount Sinai—New York, NY

Deryk Jones, MD

Deryk Jones, MD

Ochsner Sports Medicine Institute—New Orleans, LA

Brian Waterman, MD

Brian Waterman, MD

Wake Forest University School of Medicine—Winston-Salem, NC

Speakers are paid consultants of Vericel Corporation.

Venue

Music City Center Room 205 (Level 2)

201 Rep. John Lewis Way S, Nashville, TN 37203